Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

Jose Cuervo, the world’s top-selling tequila brand, says it is not a supporter of the additive-free campaign that has swept ...

Even in these tough times for the spirits industry, Jose Cuervo continues to dwarf its closest tequila competitors in terms of volume of sales (although it remains to be seen how Trump's tariffs will ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi ...

-- Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo ...